{
    "organizations": [],
    "uuid": "ac056b4fd4b11d11649954edd80f601da7a80590",
    "author": "",
    "url": "https://www.reuters.com/article/brief-pfizer-granted-fda-breakthrough-th/brief-pfizer-granted-fda-breakthrough-therapy-designation-for-trumenba-idUSASC09WRW",
    "ord_in_thread": 0,
    "title": "BRIEF-Pfizer Granted FDA Breakthrough Therapy Designation For Trumenba® (Meningococcal Group B Vaccine)",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 23, 2018 / 12:00 PM / Updated 11 minutes ago BRIEF-Pfizer Granted FDA Breakthrough Therapy Designation For Trumenba® (Meningococcal Group B Vaccine) Reuters Staff 1 Min Read \nApril 23 (Reuters) - Pfizer Inc: \n* PFIZER GRANTED FDA BREAKTHROUGH THERAPY DESIGNATION FOR TRUMENBA® (MENINGOCOCCAL GROUP B VACCINE) FOR THE PREVENTION OF INVASIVE MENINGOCOCCAL B DISEASE IN CHILDREN AGES 1 TO 9 YEARS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)",
    "published": "2018-04-23T15:00:00.000+03:00",
    "crawled": "2018-04-23T15:16:04.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "granted",
        "fda",
        "breakthrough",
        "therapy",
        "designation",
        "meningococcal",
        "group",
        "b",
        "vaccine",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "pfizer",
        "inc",
        "pfizer",
        "granted",
        "fda",
        "breakthrough",
        "therapy",
        "designation",
        "meningococcal",
        "group",
        "b",
        "vaccine",
        "prevention",
        "invasive",
        "meningococcal",
        "b",
        "disease",
        "child",
        "age",
        "year",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}